Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo

References

• Yabar CS, Winter JM. Pancreatic cancer: a review. Gastroenterol Clin North Am. 2016 Sep;45(3):429–445.https://doi.org/10.1016/j.gtc.2016.04.003. PMID: 27546841
   PubMed Web of Science ®Google Scholar
• Prabhu VV, Morrow S, Rahman Kawakibi A, Zhou L, Ralff M, Ray J, Jhaveri A, Ferrarini I, Lee Y, Parker C, et al. ONC201 and imipridones: anti-cancer compounds with clinical efficacy. Neoplasia. 2020Dec;22(12):725–744. https://doi.org/10.1016/j.neo.2020.09.005. Epub 2020 Oct 23. PMID: 33142238
   PubMed Web of Science ®Google Scholar
• Lev A, Lulla AR, Wagner J, Ralff Md, Kiehl JB, Zhou Y, Benes CH, Prabhu VV, Oster W, Astsaturov I, et al. Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. Oncotarget. 2017 Sep 12;8(47):81776–81793. https://doi.org/10.18632/oncotarget.20819. PMID: 29137221; PMCID: PMC5669847
   PubMedGoogle Scholar
• von Karstedt S, Montinaro A, Walczak H. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer. 2017 May 24;17(6):352–366. https://doi.org/10.1038/nrc.2017.28. PMID: 28536452
   PubMed Web of Science ®Google Scholar
• Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 1991 Jul 26;66(2):233–243. https://doi.org/10.1016/0092-8674(91)90614-5. PMID: 1713127
   PubMed Web of Science ®Google Scholar
• Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther. 2001 Oct;299(1):31–38. PMID: 11561060.
   PubMed Web of Science ®Google Scholar
• Allen JE, Krigsfeld G, Mayes Pa, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013 Feb 6;5(171):171ra17. https://doi.org/10.1126/scitranslmed.3004828. PMID: 23390247
   PubMed Web of Science ®Google Scholar
• Hall MD, Odia Y, Allen JE, Tarapore R, Khatib Z, Niazi TN, Daghistani D, Schalop L, Chi AS, Oster W, et al. First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report. J Neurosurg Pediatr. 2019 Apr 5;1–7. https://doi.org/10.3171/2019.2.PEDS18480. Epub ahead of print. PMID: 30952114.
   Google Scholar
• Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, et al. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 2016 Nov 8;7(45):74380–74392. https://doi.org/10.18632/oncotarget.11814. PMID: 27602582
   PubMed Web of Science ®Google Scholar
• Graves JD, Kordich JJ, Huang TH, Piasecki J, Bush TL, Sullivan T, Foltz IN, Chang W, Douangpanya H, Dang T, et al. Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. Cancer Cell. 2014 Aug 11;26(2):177–189. https://doi.org/10.1016/j.ccr.2014.04.028. Epub 2014 Jul 17. PMID: 25043603
   PubMed Web of Science ®Google Scholar
• Chae SY, Kim TH, Park K, Jin CH, Son S, Lee S, Youn YS, Kim K, Jo DG, Kwon IC, et al. Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther. 2010 Jun 9;(6):1719–1729. https://doi.org/10.1158/1535-7163.MCT-09-1076. Epub 2010 Jun 1. PMID: 20515949
   Google Scholar
• Park JS, Oh Y, Park YJ, Park O, Yang H, Slania S, Hummers LK, Shah AA, An HT, Jang J, et al. Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma. Nat Commun. 2019 Mar 8;10(1):1128. https://doi.org/10.1038/s41467-019-09101-4. PMID: 30850660
   PubMed Web of Science ®Google Scholar
• Hamacher R, Schmid RM, Saur D, Schneider G. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer. 2008 Jul 24;7:64. https://doi.org/10.1186/1476-4598-7-64. Pmid: 18652674
   PubMed Web of Science ®Google Scholar
• Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, Bayer E, Walczak H, Kalthoff H, Ungefroren H. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene. 2000 Nov 16;19(48):5477–5486. https://doi.org/10.1038/sj.onc.1203936. PMID: 11114725
   PubMed Web of Science ®Google Scholar
• Ozören N, El-Deiry WS. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia. 2002 Nov-Dec;4(6):551–557.https://doi.org/10.1038/sj.neo.7900270. PMID: 12407450
   PubMed Web of Science ®Google Scholar
• Deveraux QL, Reed JC. IAP family proteins–suppressors of apoptosis. Genes Dev. 1999 Feb 1;13(3):239–252. https://doi.org/10.1101/gad.13.3.239. PMID: 9990849
   PubMed Web of Science ®Google Scholar
• Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020 Jul;17(7):395–417.https://doi.org/10.1038/s41571-020-0341-y. Epub 2020 Mar 23. PMID: 32203277
   PubMed Web of Science ®Google Scholar
• Ralff MD, Kline CLB, Küçükkase OC, Wagner J, Lim B, Dicker DT, Prabhu VV, Oster W, El-Deiry WS. ONC201 demonstrates antitumor effects in both triple-negative and non-triple-negative breast cancers through TRAIL-dependent and TRAIL-independent mechanisms. Mol Cancer Ther. 2017 Jul;16(7):1290–1298.https://doi.org/10.1158/1535-7163.MCT-17-0121. Epub 2017 Apr 19. PMID: 28424227
   PubMed Web of Science ®Google Scholar
• Kline CL, Van den Heuvel AP, Allen JE, Prabhu VV, Dicker DT, El-Deiry WS. ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases. Sci Signal. 2016 Feb 16;9(415):ra18. https://doi.org/10.1126/scisignal.aac4374. PMID: 26884600
   PubMed Web of Science ®Google Scholar
• Deer EL, González-Hernández J, Coursen JD, Shea JE, Ngatia J, Scaife CL, Firpo MA, Mulvihill SJ. Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 2010 May;39(4):425–435.https://doi.org/10.1097/MPA.0b013e3181c15963. Erratum in: Pancreas. 2018 Jul;47(6):e37.PMID: 20418756; PMCID: PMC2860631
   PubMed Web of Science ®Google Scholar
• Ralff MD, Jhaveri A, Ray JE, Zhou L, Lev A, Campbell KS, Dicker DT, Ross EA, El-Deiry WS. TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic. Oncotarget. 2020 Oct 20;11(42):3753–3769. https://doi.org/10.18632/oncotarget.27773. PMID: 33144917
   PubMedGoogle Scholar
• Lee JW, Komar CA, Bengsch F, Graham K, GL B. Genetically engineered mouse models of pancreatic cancer: the KPC model (LSL-Kras(G12D/+);LSL-Trp53(R172H/+);Pdx-1-Cre), Its variants, and their application in immuno-oncology drug discovery. Curr Protoc Pharmacol. 2016 Jun 1;73:14.39.1–14.39.20. https://doi.org/10.1002/cpph.2. PMID: 27248578
   Google Scholar
• Wagner J, Kline CL, Zhou L, Campbell KS, MacFarlane AW, Olszanski AJ, Cai KQ, Hensley HH, Ross EA, Ralff MD, et al. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. J Clin Invest. 2018 Jun 1;128(6):2325–2338. doi: https://doi.org/10.1172/JCI96711. Epub 2018 Apr 30. PMID: 29533922
   PubMed Web of Science ®Google Scholar
• Mirandola P, Ponti C, Gobbi G, Sponzilli I, Vaccarezza M, Cocco L, Zauli G, Secchiero P, Manzoli FA, Vitale M. Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood. 2004 Oct 15;104(8):2418–2424. doi: https://doi.org/10.1182/blood-2004-04-1294. Epub 2004 Jun 17. PMID: 15205263
   PubMed Web of Science ®Google Scholar
• Hernandez-Borrero LJ, Zhang S, Lulla A, Dicker DT, El-Deiry WS. CB002, a novel p53 tumor suppressor pathway-restoring small molecule induces tumor cell death through the pro-apoptotic protein NOXA. Cell Cycle. 2018;17(5):557–567. doi:https://doi.org/10.1080/15384101.2017.1346762. Epub 2018 Feb 19. PMID: 28749203.
   PubMed Web of Science ®Google Scholar
• Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017 Dec 4;7(1):16878. doi: https://doi.org/10.1038/s41598-017-17204-5. PMID: 29203879; PMCID: PMC5715110
   PubMed Web of Science ®Google Scholar